



EARNINGS RELEASE

3Q25




São Joaquim da Barra, November 12, 2025. Vittia S.A. (VITT3: BZ) (“Vittia” or “Company”), a Brazilian company specialized in biotechnology (biopesticides and inoculants) and special plant nutrition with solutions for several agricultural crops, announces its results for the third quarter of 2025 (“**3Q25**”).

Our Business

By the end of 2024, we operated in four product divisions: Foliar Fertilizers and Industrial Products; Soil Micronutrients; Soil Conditioners and Organominerals; and Biological Products. In 1Q25, Vittia adopted a new approach to segmenting operating results as part of a strategic reorganization aimed at providing greater clarity on the performance of its main product lines and aligning its reporting structure with international market trends and the industry's most widely adopted practices. As a result, the reportable segments are now classified as: (i) Soil Fertilizers; (ii) Foliar Fertilizers and Industrial Products; and (iii) Biological and Natural Solutions.

It is important to highlight that the change in reportable segments had no impact on comparative information, since the data from the previous year were reclassified based on the new structure, enabling an adequate and consistent comparison between the periods presented.

These divisions share a centralized administration, composed of the same administrative center, including the Board of Directors and Advisory Committees, Management, Operating and Control Systems, Technology, and People, among others. We have specialized and qualified teams committed to delivering high-quality, differentiated products to continuously meet market demands, with a focus on superior productivity, financial performance, and alignment with an ESG matrix.



3Q25 Highlights



Cash generation from operating activities of **R\$ 105.9** million in 9M25, 24.3% growth, resulting in net debt of **R\$ 116.3** million and leverage of **0.89x** Adjusted EBITDA

Net revenue totaled **R\$ 325.0** million in 3Q25 (+5.0% vs 3Q24) and **R\$ 561.8** million in 9M25 (+5.8% vs. 9M24)



32.9% growth in the Soil Fertilizers segment in 9M25 (vs. 9M24)

Net revenue from the Biological and Natural Solutions line was **R\$ 108.8** million (+12.6% vs. 3Q24) and **R\$ 182.5** million in 9M25 (+2.7% vs. 9M24), even considering commercial delays at the beginning of the cycle



Adjusted EBITDA totaled **R\$ 83.5** million in 3Q25 (+0.4% vs. 3Q24) and **R\$ 69.6** million in 9M25 (-3.3% vs. 9M24)

The adjusted net result was negative by **R\$ 51.3** million in 3Q25 (+11.9% vs. 3Q24) and **R\$ 28.2** million in 9M25 (-2.7% vs. 9M24)



Payment of **R\$ 47.2** million between buyback and JCP in 9M25

Launch of sales at **Vittia México**, with **12 active registrations** in the portfolio



Launch of 2 insecticides and 1 fungicide: **Meta-Turbo Max**, **Bovéria-Turbo WP** and **Tricho-Turbo OD**

Message from Management

The third quarter of 2025, a period of great importance for the start of the 2025/26 summer crop season, was marked by a challenging scenario for Brazilian agribusiness, reflecting the persistence of tight producer margins and limited credit availability. This environment resulted in one of the largest delays in the sale of Biopesticides in Brazil over the past five years, adding a layer of complexity to the cycle.

Despite these challenges, Vittia showed the robustness of its business model and the effectiveness of its strategy, closing the quarter with a modest 5.0% increase in Net Revenue, totaling R\$ 324.9 million in 3Q25. For the first nine months of the year, Net Revenue reached R\$ 561.8 million, an increase of 5.8% compared to 9M24, reflecting the strength of the portfolio and the diversification of products and crops served by the Company.

Financial performance remained consistent within the sector's challenging environment. Operating cash generation grew 130.1% in 3Q25, reaching R\$ 33.8 million, and accumulated a 24.3% increase year-to-date, supporting a net debt of R\$ 116.3 million and leverage of 0.89x Adjusted EBITDA, a consistent level with the Company's historical financial discipline. This performance reflects strong working capital management, portfolio efficiency, and strict credit control, even in an environment of restricted liquidity conditions in the agribusiness sector.

The highlight of the period once again came from the Soil Fertilizers segment, which recorded R\$ 106.3 million in 3Q25, representing a 35.1% increase compared to the same period of the previous year. The Biological and Natural Solutions segment resulted in a 12.6% growth in net revenue compared to 3Q24, totaling R\$ 182.5 million in 9M25 (+2.7% vs. 9M24). This performance reinforces biotechnology as one of Vittia's strategic pillars and reflects the success of its innovation initiatives.

Throughout the year, Vittia has been consolidating the launch of high value-added solutions, such as *Tricho-Turbo OD*, a microbiological fungicide with an oil-dispersible (OD) formulation and the exclusive *Trichoderma asperellum* BVF24 strain, designed for superior control of soil diseases and to enhance crop vigor and productivity. Other highlights include *META-TURBO MAX*, formulated with the exclusive *Metarhizium anisopliae* BV12 strain, and *BOVERIA-TURBO WP*, formulated with the exclusive BVF15 isolate of *Beauveria bassiana*, both highly effective in pest control and preservation of beneficial insects. All these launches belong to the Biological and Natural Solutions line, reinforcing Vittia's technological leadership and commitment to innovation and agricultural productivity. In addition, *Triunfe* continues with excellent market acceptance, reinforcing the portfolio's strong performance and consolidating Vittia's recognition among producers.

Despite pressure on the sales mix and margins inherent to the slower market environment, the Company remained focused on operational efficiency. SG&A decreased slightly in the quarter, and as a result, Adjusted EBITDA for 3Q25 totaled R\$ 83.5 million, representing a 0.4% increase compared to 3Q24. Although the sector faced margin compression, our Net Debt/Adjusted EBITDA ratio remained at a comfortable and disciplined level of 0.89x, confirming our financial strength and capital management capacity in challenging cycles.

During the quarter, we completed the closure of operations at the Vittia Organo unit, located in Patos de Minas (MG). Although the project did not achieve the expected performance, its discontinuation represents a strategic move toward greater efficiency, concentrating operations at the Serrana (SP) unit and allowing resource reallocation and focus on assets with higher profitability and growth potential.

Even with delays in input negotiations, particularly in the Foliar Fertilizers line, we remain optimistic about the upcoming periods. We expect a gradual normalization of sales in 4Q25, a movement that may extend into early 1Q26, following the recovery of producers' purchasing appetite. We close the third quarter confident that our strategy, anchored in biotechnology, portfolio diversification, and financial discipline, uniquely positions us to capture this recovery and capitalize on the opportunities of the 2025/26 crop season.

Economic and Financial Performance

In thousands of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Net revenue	324,954	309,379	5.0%	561,834	530,831	5.8%
Cost of goods sold	(220,197)	(199,294)	10.5%	(400,904)	(359,341)	11.6%
Gross profit	104,756	110,085	(4.8%)	160,929	171,490	(6.2%)
Gross margin	32.2%	35.6%	-3.3 p.p.	28.6%	32.3%	-3.7 p.p.
Operating expenses (i)	(55,546)	(41,925)	32.5%	(144,404)	(131,298)	10.0%
Adjusted EBITDA	83,503	83,195	0.4%	69,584	71,945	(3.3%)
Adjusted EBITDA margin	25.7%	26.9%	-1.2 p.p.	12.4%	13.6%	-1.2 p.p.
Net financial result	(743)	347	N/A	(2,047)	2,437	N/A
Income tax and social contribution	(9,033)	(22,666)	(60.1%)	1,814	(13,697)	N/A
Net result	39,434	45,840	(14.0%)	16,292	28,933	(43.7%)
Net margin	12.1%	14.8%	-2.7 p.p.	2.9%	5.5%	-2.6 p.p.
Adjusted Net result (ii)	51,297	45,840	11.9%	28,155	28,933	(2.7%)
Net margin	15.8%	14.8%	1.0 p.p.	5.0%	5.5%	-0.4 p.p.
Investments (fixed and intangible assets)	9,552	9,137	4.5%	24,522	26,565	(7.7%)

(i) The adjustment resulting from the decommissioning of the Vittia Organo S.A. manufacturing unit can be seen in the table "Sales, general and administrative expenses (SG&A)".

(ii) The adjusted net result disregards the accounting effect resulting from the decommissioning of the Vittia Organo S.A. manufacturing unit, located in Patos de Minas/MG, already calculated at the net value of the corresponding tax effects.

Operating income


Net operating income by segment

In thousands of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Soil fertilizers	106,275	78,640	35.1%	184,567	138,871	32.9%
Foliar fertilizers and industrial products	109,844	134,115	(18.1%)	194,786	214,291	(9.1%)
Biological and natural solutions	108,835	96,625	12.6%	182,481	177,670	2.7%
Net revenue	324,954	309,380	5.0%	561,834	530,832	5.8%

Geographic breakdown

Vittia is present throughout Brazil and abroad, with revenue broken down as follows:

Breakdown of net revenue per region (R\$ million)



Gross profit and gross margin

In thousands of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Soil fertilizers	10,941	10,397	5.2%	13,612	10,172	33.8%
Gross margin	10.3%	13.2%	-2.9 p.p.	7.4%	7.3%	0.1 p.p.
Foliar fertilizers and industrial products	27,086	37,523	(27.8%)	38,856	52,556	(26.1%)
Gross margin	24.7%	28.0%	-3.3 p.p.	19.9%	24.5%	-4.6 p.p.
Biological and natural solutions	66,729	62,165	7.3%	108,461	108,761	(0.3%)
Gross margin	61.3%	64.3%	-3.0 p.p.	59.4%	61.2%	-1.8 p.p.
Gross profit	104,756	110,085	(4.8%)	160,929	171,490	(6.2%)
Gross margin	32.2%	35.6%	-3.3 p.p.	28.6%	32.3%	-3.7 p.p.

Selling, general and administrative expenses (SG&A)

In thousands of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Selling expenses	(21,282)	(20,390)	4.4%	(54,234)	(58,681)	(7.6%)
Provision for expected credit losses	(1,172)	(192)	510.4%	(390)	1,087	N/A
General and administrative expenses	(19,131)	(21,909)	(12.7%)	(76,084)	(74,394)	2.3%
Other operating income (expenses)	(13,961)	565	N/A	(13,695)	691	N/A
Total SG&A expenses	(55,546)	(41,925)	32.5%	(144,404)	(131,298)	10.0%
(+) Unit demobilization	15,568	-	N/A	15,568	-	N/A
Total SG&A excluding demobilization	(39,978)	(41,925)	(4.6%)	(128,836)	(131,298)	(1.9%)
Net revenue (%)	12.3%	13.6%	-1.2 p.p.	22.9%	24.7%	-1.8 p.p.


In September 2025, the Company completed the decommissioning of Vittia Organo S.A. manufacturing facility located in Patos de Minas, Minas Gerais as part of its strategic plan to optimize the production structure and concentrate operations in the unit located in Serrana, São Paulo. The decommissioning did not compromise the Company's overall production capacity, since production was distributed among the other manufacturing units. The total accounting impact associated with the decommissioning amounted to R\$ 15.6 million and was fully recognized in the Company's results for the fiscal year.

SG&A totaled R\$ 128.8 million in 9M25, representing 22.9% of net revenue, a 1.8 p.p. decrease compared to 9M24. This result reflects the cost rationalization and optimization initiatives undertaken in the previous fiscal year, the effects of which continued throughout 2025. The Company remains focused on its operational efficiency strategy, preserving its commercial capacity and sustaining its growth.

Adjusted EBITDA and Adjusted EBITDA Margin

The Company's adjusted EBITDA (excluding the adjustment to the present value of accounts receivable and non-recurring events) was R\$ 69.6 million in 9M25 (-3.3% vs. 9M24), with an adjusted EBITDA margin of 12.4% (-1.2 p.p. vs. 9M24), mainly due to the reduction in gross profit.

Adjusted EBITDA Performance (R\$ million)



Adjusted EBITDA margin performance



(1) SGA = General, administrative, other and non-recurring expenses / AFDA = Allowance for Doubtful Accounts / D&A = Depreciation and amortization / PVA = Present value adjustment

Reconciliation of net income and adjusted EBITDA

In thousands of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Net result	39,434	45,840	(14.0%)	16,292	28,933	(43.7%)
(+) Income tax and social contribution	9,033	22,666	(60.1%)	(1,814)	13,697	N/A
(+) Net financial income (loss)	743	(347)	N/A	2,047	(2,437)	N/A
(+) Depreciation and amortization	6,644	5,554	19.6%	18,971	16,228	16.9%
EBITDA (i)	55,854	73,713	(24.2%)	35,497	56,421	(37.1%)
EBITDA Margin (i)	17.2%	23.8%	-6.6 p.p.	6.3%	10.6%	-4.3 p.p.
(+) Present value adjustment – PVA	12,081	9,482	27.4%	18,519	15,524	19.3%
(+) Unit demobilization (ii)	15,568	-	N/A	15,568	-	N/A
Adjusted EBITDA (iii)	83,503	83,195	0.4%	69,584	71,945	(3.3%)
Adjusted EBITDA margin (iii)	25.7%	26.9%	-1.2 p.p.	12.4%	13.6%	-1.2 p.p.

(i): EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-accounting measure disclosed by the Company under CMV Instruction 527 of October 4, 2012 ("CMV Instruction 527"), reconciled with its financial statements, and consists of net income plus net financial result, income tax and social contribution expenses, and depreciation and amortization expenses and costs. The EBITDA margin is calculated by dividing EBITDA by the net operating income.

(ii) In September 2025, the Company completed the decommissioning process of the Vittia Organo S.A. manufacturing unit located in Patos de Minas/MG, in line with the strategic plan to optimize the production structure and concentrate operations in the units located in Serrana/SP. The decommissioning did not compromise the Company's overall production capacity, since production was redistributed among the other manufacturing units. The total accounting effect resulting from the decommissioning amounted to R\$ 15,568 thousand, which was fully recognized in the results of the fiscal year.

(iii) The adjusted EBITDA is a non-accounting measure according to the accounting practices adopted in Brazil and accepted by IFRS. The adjusted EBITDA is calculated based on EBITDA plus the present value adjustments of accounts receivable and other non-recurring events. The adjusted EBITDA margin is calculated by dividing adjusted EBITDA by the net operating income.

Financial result

In thousands of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Interest income and discounts	592	473	25.2%	1,829	1,623	12.7%
Present value adjustment (i)	5,543	4,175	32.8%	18,066	15,999	12.9%
Income from financial investments	1,230	797	54.3%	3,263	2,445	33.5%
Interest expenses	(6,662)	(4,308)	54.6%	(17,130)	(12,110)	41.5%
Discounts granted	(116)	(262)	(55.7%)	(1,321)	(1,032)	28.0%
Interest on right of use	(580)	(705)	(17.7%)	(2,109)	(2,106)	0.1%
Tax on financial transactions (IOF) and other	(912)	(102)	794.1%	(1,188)	(362)	227.3%
Exchange variation, net (ii)	(235)	1,146	N/A	8,504	(5,524)	N/A
Gains (losses) with derivatives (ii)	397	(868)	N/A	(11,961)	3,505	N/A
Net financial result	(743)	347	N/A	(2,047)	2,437	N/A

(i) The Present Value Adjustment (PVA), which includes our sales realized in the "Crop Period". In this procedure, the "Accounts Receivable" resulting from such sales are adjusted to their present value through discounts that consider pre-fixed embedded interest. To bring the "Accounts Receivable" to present value we use the average weighted funding cost. This practice has the following impact on our balance sheet and results: in the first moment, the PVA is deducted from our "Accounts Receivable" through an account that reduces the balance sheet, while gross revenue is also deducted at the same amount. With time, the amount deducted is accrued in the financial result under interest gains, reducing the value of the account that reduces the "Accounts Receivable". The monthly accrual is based on the rate used for the discount at the initial moment. Accordingly, upon payment, the value of "Accounts Receivable" is offset by fully debiting the cash account, and the total gross revenue arising from the sale in installments will be partially accrued as operating income upon delivery of the good and partially accrued every month as financial revenue until the payment is made.


(ii) To protect itself against risks from exchange rate variations, the Company uses derivative hedging instruments, mainly foreign exchange swaps and NDFs (non deliverable forwards). NDFs are generally used to manage currency exposure on balance sheets, avoiding or minimizing the mismatch on accounts receivable, operating liabilities, and accounts payable that are denominated in dollars. Swaps are usually contracted through operations known as "4131 swaps". In these operations, the Company contracts a debt instrument in foreign currency (Dollar or Euro) with a financial institution, while contracting, at the same time, a swap operation, exchanging this obligation in foreign currency (long end for the Company) for yields based on the variation of Interbank Deposit Certificates - CDI, plus a spread (short end for the Company). These operations are carried out with the same counterparty and with the same amounts and maturity dates. Swaps are classified as fair value derivatives and their results are accounted for as gains (losses) on derivatives. Foreign currency debt is classified under loans and financing, with the result from the exchange variation and interest accounted for as financial expenses.

The net financial result in 3Q25 was a negative R\$ 0.7 million (reversal of the positive result of R\$ 0.3 million in 3Q24). In 9M25, the result was a negative R\$ 2.0 million (reversal of the positive result of R\$ 2.4 million in 9M24). The variation in the result for the period is mainly attributed to the increase in average net debt in 9M25 (+21.7% compared to 9M24) and the increase in the interest rate in the same period, resulting in higher financial charges.

Cash flow management and indebtedness

Cash flow management

Cash flow (R\$ million)



In Thousand of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Cash Generation	12,422	21,051	(41.0%)	21,556	(22,985)	N/A
Operating activities	33,841	16,664	103.1%	105,916	85,230	24.3%
Investments	(9,733)	(8,335)	16.8%	(23,355)	(25,763)	(9.3%)
Financing	(11,686)	12,722	N/A	(61,005)	(82,452)	(26.0%)
Cash and cash equivalents at beginning of period	63,607	38,794	64.0%	54,473	82,829	(34.2%)
Cash and cash equivalents at end of period	76,029	59,844	27.0%	76,029	59,844	27.0%

The cash variation in 9M25 was positive by R\$ 21.6 million due to the amortization of financing, which reached R\$ 61.0 million (-26.0% vs. 9M24) and investments, which totaled R\$ 23.4 million (-9.3% vs. 9M24), partially offset by operating activities, which totaled R\$ 105.9 million (+24.3% vs. 9M24).

Indebtedness

The Company's gross debt reached R\$ 192.3 million in 9M25 (+14.5% vs. 9M24 and -3.6% vs. 2024), while net debt registered R\$ 116.3 million (+7.6% vs. 9M24 and -19.8% vs. 2024). The net debt/EBITDA ratio came to 0.89x (-0.04x vs. 9M24 and -0.20x vs. 2024) mainly due to the variation in net debt in the period.

In thousands of R\$, except %	3Q25	3Q24	Chg. %	2024	Chg. %
Loans and financing (current)	142,741	96,485	47.9%	132,058	8.1%
Loans and financing (non-current)	49,539	71,383	(30.6%)	67,440	(26.5%)
Gross debt	192,280	167,868	14.5%	199,498	(3.6%)
(-) Cash and cash equivalents	(76,029)	(59,844)	27.0%	(54,473)	39.6%
Net debt (i)	116,251	108,024	7.6%	145,025	(19.8%)
<i>LTM Adjusted EBITDA</i>	<i>130,922</i>	<i>116,756</i>	<i>12.1%</i>	<i>133,282</i>	<i>(1.8%)</i>
Net Debt/LTM EBITDA	0.89x	0.93x	-0.04x	1.09x	-0.20x

CAPEX and Research, Development and Innovation

Investments in CAPEX reached R\$ 24.5 million in 9M25 (-7.7% vs. 9M24). These CAPEX investments are primarily focused on operational improvements that can generate productivity gains and cost reductions, without focusing on large-scale projects. The most significant investment this year is the plant to support the launch and growth of Triunfe. The CAPEX strategy seeks to adapt to the current moment of increased conservatism in agribusiness and rising interest rates in the country, seeking the efficient allocation of capital.

Fertilizer and Atypical Pesticides Plant

Vittia's investments in the concentrated suspension line to support the launch of Triunfe, where R\$ 4.2 million was invested in 9M25, out of a total of R\$ 7.3 million planned for 2025. This investment is being used to build a new concentrated suspension line and adapt the layout of the bottling area. Located in São Joaquim da Barra/SP, this plant aims to increase annual production capacity to 4.5 million liters of concentrated suspension products.

R&D Investments

The Company generates value through integrated teams, combining knowledge and experience from the areas of R&DI, Market Development and Regulatory Affairs. At the end of 3Q25, we had 52 R&DI professionals, 35 of whom were exclusively dedicated to this area.

In 9M25, the Company invested R\$ 20.3 million in research and development, which represents a 5.0% reduction compared to the same period of the previous year. This variation reflects, in part, a lower intensity of field studies in the period, influenced by the readjustment of the technical support structure in the field. This amount corresponds to 3.6% of the Company's net revenue (-0.4 p.p. vs. 9M24). It is worth noting the seasonal nature of Capex investments, which does not indicate a reduction in investments by the Company in 2025.

Research and Development Investments

In thousand of R\$	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Biological products	5,361	4,871	10.1%	15,395	15,980	(3.7%)
Fertilizers	1,591	1,582	0.6%	4,901	5,383	(9.0%)
Total	6,953	6,454	7.7%	20,296	21,363	(5.0%)
Capex	538	82	558.1%	703	1,631	(56.9%)
Opex	6,415	6,372	0.7%	19,593	19,732	(0.7%)
Net revenue (%)	2.1%	2.1%	-	3.6%	4.0%	-0.4 p.p.

Key developments

By the end of the third quarter of 2025, Vittia launched two new high-performance biological insecticides:

- **META-TURBO MAX:** formulated with an exclusive strain, the fungus *Metarhizium anisopliae* BV12 and a unique formulation in a concentrated suspension obtained through liquid fermentation. Its main advantages include high virulence and proven efficacy in controlling pests such as sugarcane boll weevils, fall armyworms, false loopers, boll weevils, brown stink bugs, and coffee leaf miners. The product protects the pests' natural enemies and reduces the likelihood of resistant pests emerging.
- **BOVERIA-TURBO WP:** this is a microbiological insecticide and acaricide formulated with the exclusive BVF15 isolate of the fungus *Beauveria bassiana*. Its wettable powder (WP) formulation protects spores from ultraviolet radiation and is easy to mix in a tank. Indicated for the control of whitefly, coffee borer, sugarcane boll weevil, and corn leafhopper, the product stands out for its rapid action, with insect colonization within 72 hours and high compatibility with the preservation of natural enemies, making it an option for other pest management strategies.
- **TRICHO-TURBO OD:** fungicide developed from the exclusive strain *Trichoderma asperellum* BVF24. The liquid formulation in oil dispersion (OD) protects microorganism spores, ensuring greater virulence in the field. It is widely used to control soil diseases such as wilts and damping-off, as well as nematodes. In addition to its action against pathogens, it favors plant development, promoting greater vigor and productivity.

With these new launches, Vittia strengthens its portfolio of biological solutions and reaffirms its commitment to Brazilian agribusiness, delivering effective, sustainable, and high-performance technologies for controlling major plant pests and diseases. Furthermore, the Company obtained 4 new registrations, 2 new recommendations for biological use/targets, and 1 renewal of its Temporary Special Registration (RET).

The first half of 2025 also marked the start of commercialization for Vittia Mexico, with a portfolio of 12 active registrations in the country.

Human Resources

We ended 3Q25 with 1,120 employees, compared to 1,158 in the previous quarter (-3.3% vs. 2Q25 and -12.4% vs. 3Q24). All our employees, including those under temporary employment contracts, are directly hired by the Company under the Brazilian Consolidation of Labor Laws (CLT).

The Company maintains a close relationship with the unions that represent its employees. Collective agreements and conventions, as well as those negotiated directly, have a usual duration of 12 months. Vittia also complies with applicable labor laws and conditions established in collective bargaining agreements signed with labor unions, applying them equally to unionized and non-unionized employees.

Capital Markets

The shares of Vittia S.A. (B3: VITT3) have been traded since the IPO, on September 1, 2021, in the Novo Mercado segment of B3, the highest Corporate Governance level in the Brazilian stock market. The Company is also included in the IGC (Special Corporate Governance Stock Index), IGC-NM (Novo Mercado Corporate Governance Equity Index), and ITAG (Special Tag-Along Stock Index) indexes.

Share capital: Vittia's share capital was constituted, on 09/30/2025, by 150.3 million common shares (ON), of which 63.7% belonged to controlling shareholders, 2.5% to the Company's management, 31.7% were in free circulation on the market ("free float") and 2.1% were shares held in treasury.

Market cap: At the end of the quarter, VITT3 share was priced at R\$ 5.06, representing a market cap of R\$ 760.6 million, compared to R\$ 729.0 million at the end of the previous quarter, an increase of 4.3% or R\$ 31.6 million.

Free-float Breakdown: At the end of 3Q25, the free float was distributed as follows: individual investors held 10.1% (vs. 11.2% in 2Q25), local institutional investors held 87.6% (vs. 86.1% in 2Q25), and foreign investors held 2.2% (vs. 2.7% in 2Q25).

Number of shareholders: At the end of the quarter, the Company had 4.3 thousand shareholders, compared to 4.4 thousand at the end of 2Q25, reduction of 4.4%.

Average Daily Trading Volume ("ADTV"): The average daily trading volume was R\$ 0.8 million in 3Q25, compared to R\$ 1.3 million in the previous quarter, decrease of R\$ 0.5 million or 40.3%.

Dividend distribution: By the end of 9M25, the Company had paid R\$ 33.8 million in dividends, as JCP, paid on 01/06/2025, 05/16/2025, 08/13/2025 and 09/03/2025.

Distribuição de resultados: In 9M25, the Company paid R\$ 33.8 million in dividends, as JCP, paid on 01/06/2025, 05/16/2025, 08/13/2025 and 09/03/2025.

In the RCA held on July 14, 2025, the declaration of distribution of JCP calculated in the period from January to July 2025 was approved, in the gross amount of R\$ 20.8 million (R\$ 0.14040135117 per share) based on the shareholding position of July 18, 2025. The first installment, in the amount of R\$ 7.0 million (R\$ 0.04731352488 per share), was paid on August 13, 2025 and the second installment, in the amount of R\$ 6.0 million (R\$ 0.04055444989 per share) was paid on 09/03/2025, and the third installment, in the amount of R\$ 7.8 million (R\$ 0.05253337640) will be paid on a date to be defined by the Company.

Furthermore, at the Shareholders' Meeting held on October 29, 2025, the declaration of distribution of interest on equity accrued in the period from August to October 2025 was approved, in the gross amount of R\$ 9.5 million (R\$ 0.06474713761 per share) based on the shareholding position of November 3, 2025, with the payment date to be defined by the Company.

Share buyback program: In the first nine months of 2025, the Company repurchased the equivalent of R\$ 13.4 million, taking into account shares repurchased under the 4th Share Buyback Program. At the end of October, the Company had 3,235,979 shares held in treasury.

On October 29, 2025, the Company announced that the Board of Directors approved the 5th Share Buyback Program, with up to 4,500,000 common shares to be acquired, representing, on this date, approximately 9.0% of the outstanding shares issued by the Company, with a maximum term of 12 months.

Furthermore, on October 29, 2025, the Company announced the cancellation of 3,000,000 common shares issued by the Company and held in treasury, acquired under the Company's 4th share buyback program, without reducing the share capital, especially for the purposes of Article 9 and Article 10 of CVM Resolution No. 77, of March 29, 2022 ("CVM Resolution No. 77/22"), against the balances of available profit reserves, excluding the balances of the reserves indicated in item I of paragraph 1 of Article 8 of CVM Resolution No. 77/22. As a result, the Company's share capital was divided into 147,314,018 shares.

Basic Financial Statements

Income Statement for the Year – 3Q25 vs. 3Q24 and 9M25 vs. 9M24

Income Statement (R\$ thousand)	3Q25	3Q24	Chg. %	9M25	9M24	Chg. %
Net revenue	324,954	309,379	5.0%	561,834	530,831	5.8%
Sales costs	(220,197)	(199,294)	10.5%	(400,904)	(359,341)	11.6%
Gross profit	104,756	110,085	(4.8%)	160,929	171,490	(6.2%)
<i>Gross margin</i>	32.2%	35.6%	(9.4%)	28.6%	32.3%	(11.3%)
Selling expenses	(19,742)	(20,390)	(3.2%)	(52,694)	(58,681)	(10.2%)
Provision for expected credit losses	(1,172)	(192)	510.4%	(390)	1,087	N/A
General and administrative expenses	(20,671)	(21,909)	(5.7%)	(77,624)	(74,394)	4.3%
Other net operating income (expenses)	(13,961)	565	N/A	(13,695)	691	N/A
SG&A expenses	(55,546)	(41,926)	32.5%	(144,403)	(131,297)	10.0%
Operating profit	49,210	68,159	(27.8%)	16,526	40,193	(58.9%)
Financial income	8,213	7,318	12.2%	33,910	26,187	29.5%
Financial expenses	(8,956)	(6,971)	28.5%	(35,957)	(23,750)	51.4%
Financial result	(743)	347	N/A	(2,047)	2,437	N/A
Profit (loss) before income tax and social contribution	48,467	68,506	(29.3%)	14,478	42,630	(66.0%)
Current and Deferred Income Tax and Social Contribution	(9,033)	(22,666)	(60.1%)	1,814	(13,697)	N/A
Result for the period	39,434	45,840	(14.0%)	16,292	28,933	(43.7%)
<i>Net margin</i>	12.1%	14.8%	(2.7%)	2.9%	5.5%	(2.6%)

Cash Flow Statements – 9M25 vs. 9M24

In thousands of R\$, except %	9M25	9M24
Cash Flow from Operating Activities		
Result for the period	16,292	28,933
Adjustments for:		
Depreciation and amortization	18,971	16,228
Residual cost of sold/written-off fixed assets	8,202	1,314
Current taxes	1,181	8,261
Deferred taxes	(2,995)	5,436
Provision for bônus	-	4,251
Provision for commissions	9,674	6,644
Interest and monetary variations on loans and financing	20,461	12,261
Interest on lease liabilities	2,325	2,125
Present value adjustment variation	249	(516)
Provision for doubtful accounts	390	(1,087)
Losses with bad debts	-	-
Fair value of derivate financial instruments	11,960	(3,505)
Provision for contingencies	78	387
Exchange Variation	(6,466)	5,189
Change in working capital		
Increase in trade receivables	64,256	35,529
Increase in inventories	(43,974)	(23,849)
Increase (decrease) in taxes recoverable	5,554	1,489
Increase in advances to suppliers	1,138	(6,313)
(Increase) decrease in other receivables	2,589	(2,238)
Increase (decrease) in suppliers	12,594	12,068
Increase (decrease) in payroll and social security charges	822	3,721
Increase in taxes and contributions payable	(36)	(1,262)
Increase in advances from customers	9,924	9,225
Increase in other accounts payable	(5,353)	(5,377)
Cash generated by Operations	127,836	108,917
Income tax and social contribution paid	(1,118)	(826)
Interest paid on lease liabilities	2,325	(2,125)
Interest paid on loans and financing	(18,477)	(20,736)
Net cash from operating activities	105,916	85,230

Cash Flow Statements – 9M25 vs. 9M24 (continued)
Cash flows from investing activities

Receivables from the sale of fixed assets	1,167	802
Investment acquisition	-	-
Acquisition of Investments	-	-
Acquisition of fixed assets	(24,593)	(26,594)
Increase in intangible assets	71	29
Net cash flow used in investing activities	(23,355)	(25,763)

Cash flows from financing activities

Loans and financing raised	118,000	188,000
Payment of lease liabilities	(5,223)	(3,715)
Payment of loans and financing	(120,735)	(184,396)
Realized derivative financial instruments	(5,838)	(6,409)
Acquisition of treasury shares	(13,420)	(37,741)
Dividends paid	(33,789)	(38,191)
Net cash flows generated by financing activities	(61,005)	(82,452)

Increase (decrease) in cash and cash equivalents, net	21,556	(22,985)
Cash and cash equivalents at the beginning of the period	54,473	82,829
Cash and cash equivalents at the end of the period	76,029	59,844

Balance Sheet as of September 30, 2025 and December 31, 2024

In thousands of R\$, except %	3Q25	2024
Assets		
Current assets	567,374	590,289
Cash and cash equivalents	76,029	54,473
Derivative Financial Instruments – Assets	-	4,155
Trade receivables	264,757	337,383
Inventories	205,258	161,284
Taxes recoverable	8,507	14,756
Current tax asset	5,569	7,199
Advances to suppliers	3,352	4,489
Other receivables	3,902	6,550
Non-current assets	362,376	362,889
Non-current receivables	24,851	21,387
Trade receivables	3,651	3,066
Taxes recoverable	5,478	5,657
Deferred tax asset	14,272	11,277
Other receivables	1,450	1,387
Permanent	337,525	341,502
Investments	255	256
Fixed assets	298,596	294,961
Right of use	24,818	31,041
Intangible assets	13,856	15,244
Total assets	929,750	953,178
Liabilities and equity		
Current liabilities	241,740	221,417
Suppliers	27,776	15,182
Loans and financing	142,741	132,058
Derivative Financial Instruments	2,388	107
Payroll and social security charges	22,722	21,810
Taxes and contributions payable	4,222	4,258
Current tax liabilities	741	5,164
Advances from customers	15,626	5,702
Dividends to distribute and interest on equity	6,929	22,200
Lease liability	7,335	4,878
Other accounts payable	11,260	10,058
Non-current liabilities	70,466	96,844
Loans and financing	49,539	67,440
Taxes and contributions payable	-	-
Provision for contingencies	680	602
Lease liability	20,247	28,802
Total equity attributable to controlling shareholders	617,380	634,772
Non-controlling interests	164	145
Total liabilities	312,206	318,261
Total liabilities and equity	929,750	953,178

Investor Relations

Alexandre Del Nero Frizzo – CFO and IRO

Ana Laura Pavan – IR and Sustainability Coordinator

Laís Nunes – IR Analyst

 ri@vittia.com.br

 ri.vittia.com.br